Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
Outlook Therapeutics, Inc. (OTLK)
Last outlook therapeutics, inc. earnings: 2/14 08:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. “We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “Laura’s two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value opportunities, will be instrumental as we advance our mission to deliver a differentiated ophthalmic formulation of bevacizumab and pursue opportunities to maximize long-term shareholder value.” In her role as Vice President of Corporate Strategy and Business Development, Ms. Cantrell will be re
Show less
Read more
Impact Snapshot
Event Time:
OTLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OTLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OTLK alerts
High impacting Outlook Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OTLK
News
- Oncobiologics (NASDAQ:OTLK) had its price target lowered by analysts at Chardan Capital from $3.00 to $1.00. They now have a "neutral" rating on the stock.MarketBeat
- Oncobiologics (NASDAQ:OTLK) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OTLK&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZeMarketBeat
- Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again [Seeking Alpha]Seeking Alpha
- Outlook Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]Yahoo! Finance
- Outlook Therapeutics Announces New Employment Inducement GrantsGlobeNewswire
OTLK
Earnings
- 8/14/25 - Miss
OTLK
Sec Filings
- 12/19/25 - Form 10-K
- 12/19/25 - Form 8-K
- 11/3/25 - Form 8-K
- OTLK's page on the SEC website